# Elotuzumab

Source: https://onco.cc/drugs/elotuzumab/  
OnCo record `elotuzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An immune-stimulating antibody for myeloma that works only in combination, adding benefit to lenalidomide or pomalidomide.

## Summary

Elotuzumab is a monoclonal antibody against SLAMF7 (CS1), a surface protein on both myeloma cells and natural killer cells. It marks myeloma cells for NK-mediated antibody-dependent cellular cytotoxicity and simultaneously activates the NK cells, but it has no single-agent activity and is always combined with an immunomodulatory drug and dexamethasone. ELOQUENT-2 (2015) showed median progression-free survival of 19.4 versus 14.9 months when added to lenalidomide-dexamethasone in patients after 1 to 3 prior therapies, leading to US approval in 2015. ELOQUENT-3 (2018) supported a second approval with pomalidomide-dexamethasone after at least two therapies. CD38 antibodies have largely displaced it, but it remains an option in daratumumab-refractory disease and is generally well tolerated. The key idea is an antibody that works only by recruiting the patient's own immune cells.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Empliciti
- Modality: Anti-SLAMF7 monoclonal antibody
- Mechanism: Binds SLAMF7 (CS1) on myeloma cells and NK cells, enhancing NK-mediated ADCC; no single-agent activity.
- Approvals: US 2015: Multiple myeloma after 1-3 prior therapies, with lenalidomide-dexamethasone; US 2018: With pomalidomide-dexamethasone after ≥2 therapies

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Elotuzumab
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=elotuzumab

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [ADCC (antibody-dependent cellular cytotoxicity)](https://onco.cc/terms/adcc/)
- trials: [A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez](https://onco.cc/trials/nct06208150/), [A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre](https://onco.cc/trials/nct03989414/), [A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re](https://onco.cc/trials/nct05730036/), [MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other](https://onco.cc/trials/nct06152575/), [Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto](https://onco.cc/trials/nct06158841/)
- targets: [SLAMF7 (CS1)](https://onco.cc/targets/slamf7/)

---
JSON: https://onco.cc/api/v1/entities/elotuzumab.json